The acute coronary syndrome sub-segment under application segment is projected to dominate the global cardiac biomarkers market during the forecast period. It is likely to occur due to a rise in the investment by various health institutes in biomarker testing for early detection of the disease. This information is given in an upcoming report by Fortune Business Insights, titled, “Cardiac Biomarkers Market Size, Share and Global Trend By Type (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), Myoglobin), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure), By End User (Hospitals, Diagnostic Centers, Homecare Settings) and Geography Forecast till 2026.”
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cardiac-biomarkers-market-101233
Roche, a multinational healthcare company, headquartered in Switzerland, announced that FDA approved it’s Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test in January 2017. The test would support in promptly identifying patients who are suspected of myocardial infarction. The test is currently available across the globe for the last seven years. During its presence in the global market, extensive research and studies about it were conducted in almost 600 publications. Emergency clinicians and doctors nowadays look for safety and accuracy in detecting chances of heart attacks. It is often fueled by troponin assay. But FDA’s approval of Elecsys would boost the emergency medication sector.
Fortune Business Insights has further profiled some of the prominent market players operating in the global cardiac biomarkers market. They are as follows:
- Thermo Fisher Scientific
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd.
- Randox Laboratories Ltd.
- Beckman Coulter, Inc.
- Dickinson and Company
- Dickinson and Company
- bioMérieux SA
- Other key market players
Request a Sample Copy of the Global Cardiac Biomarkers Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-biomarkers-market-101233
Global Cardiac Biomarkers Market Segmentation
- Creatine kinase-MB (CK-MB)
- B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
By End User
- Diagnostic Centers
- Homecare Settings
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
More Trending Topics From Fortune Business [email protected]